Table 2

FSL-1 application significantly protected against genital HSV-2 challenge in mice.

HSV-2 dose

FSL-1 2 μg 24 h priora

FSL-1 2 μg 6 h prior

DPBS vehicle control


(pfu)

%Infectedb

%Survivalc

%Infected

%Survival

%Infected

%Survival


1 × 101

NDd

ND

ND

ND

30

70

1 × 102

30

70

10e

90

70

50

1 × 103

50e

50e

100

40

100

0

1 × 104

90

10

100

0

ND

ND


ID50f

760 (80-7000)

260 (10-6000)

31 (10-80)

LD50g

760 (80-7000)

660 (300-1000)

68 (7-700)


a Intravaginal application of FSL-1 or DPBS vehicle control at indicated times prior to vaginal HSV-2 inoculation (n = 10 mice/treatment at each HSV-2 dose).

b Percentage of mice with infectious virus in d2 vaginal swabs.

c Percentage of mice that survived HSV-2 vaginal challenge up to d14 PI.

d ND, not determined.

e p < 0.05 compared to vehicle control (Fisher's exact test).

f Dose of the virus required to infect 50% of the mice based on %Infected data; ID50 (95% confidence interval).

g Dose of the virus required to cause lethal outcomes in 50% of the mice based on % survival data; LD50 (95% confidence interval).

Rose et al. Virology Journal 2009 6:195   doi:10.1186/1743-422X-6-195

Open Data